key: cord-0999730-sag7hr9e
authors: Marcolino, Vanessa Aparecida; Pimentel, Tatiana Colombo; Barão, Carlos Eduardo
title: What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results
date: 2020-08-08
journal: Eur J Pharmacol
DOI: 10.1016/j.ejphar.2020.173467
sha: cc4da60e00fb59db04097efde1dfa6546d1c5ce0
doc_id: 999730
cord_uid: sag7hr9e

The end of 2019 was marked by the emergence of a new type of coronavirus (SARS-CoV-2), which has killed more than 240,000 people around the world so far. Several clinical studies are being performed to test possible drugs in response to the COVID-19 outbreak; however, there is still no treatment that is completely effective. Our goal in this paper is to bring together the results of main studies carried out with different drugs in order to help spread the knowledge about possible treatments for COVID-19 that have been suggested so far.

In the first half of April, the world reached catastrophic numbers due to the 28 spreading of the COVID-19 pandemic. At a global level, more than 3.4 million 29 people have been infected and more than 240,000 have died (WHO, 2020a) . 30 The virus has reached almost all the countries in the world and its spread has 31 been proven to occur mainly through saliva spray disseminated by infected concern for public health. SARS-CoV-2 is the causative agent of COVID-19. Ivermectin has also been studied due to its antiviral activity against a wide 

On the other hand, other aspects of the convalescent plasma should be 323 noted. For instance, it varies from individual to individual depending on the type 324 of antibody and its concentrations. Therefore, the plasma needs adjusting for 325 the transfusion process. For this therapy to be effective, the creation of blood 326 banks that store standardized and characterized frozen plasma is necessary so 327

WHO. Coronavirus disease 2019 (COVID-19) situation report -105. Geneva: 586 WHO, (2020a), 04 May

Update: Safety and efficacy of hydroxychloroquine or 588 chloroquine for treatment of COVID-19

Analysis of therapeutic targets for SARS-591

CoV-2 and discovery of potential drugs by computational methods

CoV-2 is the causative agent of COVID-19

• We have at the moment only palliative pharmacological alternatives

• Some drugs: Chloroquine, Hydroxychloroquine, Antivirals, Plasma, Ivermectin, Anticoagulant